SOCIETY OF HEMATOLOGIC ONCOLOGY
SOHO 2026September 9-12, 2026 Houston
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| ABCL-026 | A Manifold-Based Topological Approach for Identifying Stage-Divergent Apoptotic Signatures in DLBCL | Alamin Mustafa |  Received |
 |
|||
| AML-037 | Topological Reconstruction of DNA Repair Signatures and Survival Divergence in Acute Myeloid Leukemia | Alamin Mustafa | Received |
|
|||
| MM-116 | AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study | Karun Neupane | Received |
|
|||
| CLL-119 | Clinical Outcomes and Predictors of Early Inpatient CAR-T Administration Within 48 Hours: A Nationwide Analysis | Fiqe Khan | Received |
|
|||
| CT-227 | Measurable Residual Disease by Circulating Tumor DNA in Patients With Third-Line or Later Relapsed or Refractory Follicular Lymphoma Treated With Lisocabtagene Maraleucel in TRANSCEND FL | Alex Verdeur | Received |
|
|||
| CT-228 | Outcomes of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: First Real-World Data From the CIBMTR | Alex Verdeur | Received |
|
|||
| ALL-280 | Topological Simplification and Loss of Regulatory Complexity in the DNA Repair Pathway of Acute Lymphoblastic Leukemia | Alamin Mustafa | Received |
|
|||
| ABCL-346 | Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma | Alex Verdeur | Received |
|
|||
| ABCL-438 | Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LCBL): Updated efficacy and safety from the Phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups | Isobel Neill | Received |
|
|||
| ABCL-483 | Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO | Isobel Neill | Received |
|
|||
| AML-623 | Long-term follow-up of pediatric/young adult patients with relapsed/refractory KMT2Ar acute leukemia treated with revumenib in AUGMENT-101 | Anna Sitarski | Received |
|
|||
| AML-632 | Revumenib Therapy Post-Hematopoietic Stem Cell Transplant for Patients With Relapsed/Refractory KMT2Ar, NPM1m, and NUP98r Acute Myeloid Leukemia: Post Hoc Analysis of Outcomes From AUGMENT-101 | Anna Sitarski | Received |
|
|||
| AML-712 | Revumenib plus intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708 | Anna Sitarski | Received |
|
|||
| AML-723 | Clinical Activity of Revumenib in Patients With Relapsed/Refractory NUP98-Rearranged Acute Leukemias | Anna Sitarski | Received |
|
|||
| ABCL-736 | Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study | Isobel Neill | Received |
|
|||
| AML-773 | Efficacy of Revumenib in Acute Myeloid Leukemia Harboring NPM1-Mutated Co-Mutations: Post Hoc Analysis of AUGMENT-101 | Anna Sitarski | Received |
|
|||
| TCL-1326 | Treatment Outcomes and Prognostic Factors in Elderly Patients with Newly Diagnosed Peripheral T-Cell Lymphoma | Omar Elghawy | Received |
|
|||
SOHO 2026
September 9-12, 2026 Houston
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 09/09/2026 TO 09/09/2026
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 28/08/2026
|
|
